louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02128438: Most People With Low Back Pain Have Associated Cervicothoracic Musculoskeletal Dysfunction: an Observational Study
Official title: Most People With Low Back Pain Have Associated Cervicothoracic Musculoskeletal Dysfunction: an Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Low Back Pain
Lead sponsor: Swami Vivekanand National Institute of Rehabilitation Training and Research
Sponsor class: OTHER
First posted: 2014-05-01
Enrollment: 940
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Persons with low back pain who had attended our hospital and sub centres with a complaint of low back pain

Brief summary: In general , the diagnosis of back pain can be broken into three major categories: Mechanical ( Osteoarthritis , Spinal stenosis , Spondylolisthesis) ; Non- mechanical ( Tumor , Infection , Inflammatory arthritis ) and Miscellaneous (Osteoporosis , Psychosomatic disorders , neuropathic joints , visceral diseases ). Although 98% of LBP may be caused by mechanical factors, it is the other 2% caused by malignancy, infection, visceral diseases and other red herrings that must be considered most seriously.

The investigators have observed in their practice that lateral pressure on 5th lumbar vertebra sometimes gives rise to cervicothoracic pain and central PA pressure over cervicothoracic spines reproduce original low back and leg pain. So the question arises whether Cervico-thoracic dysfunction is associated with low back pain with or without radiation to lower extremities?


Eligibility criteria: Inclusion Criteria:

* mechanical low back pain with or without radiation to lower limb.

Exclusion Criteria:

* any recent trauma or fractures to cervico-thoracic junction, osteoporosis, inflammatory arthritis, tuberculosis, bone disease, congenital deformity
* vascular disorders
* rapidly progressing neurological deficits
* sudden onset of neurological deficits and all red flags to manual therapy.

Primary outcomes:
measure: incidence of cervico-thoracic dysfunction in patients with low back pain
timeFrame: The outcome measure, viz. the incidence of cervico-thoracic dysfunction was ascertained immediately at the time of initial physical assessment. No follow-up was required.
Secondary outcomes:
Other outcomes:
Locations:
city: Olatpur, Cuttack Dt
country: India
facility: SVNIRTAR
state: Odisha
Study officials:
affiliation: Swami Vivekanand National Institute of Rehabilitation Training and Research
name: Patitapaban Mohanty, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: SCB medical college and hospital, Cuttack
name: Basant K Behera, M.S (Ortho)
role: STUDY_CHAIR
References:
Clinical trial NCT01331538: Temporomandibular Dysfunction and Cervical Posture
Official title: Correlation Between Temporomandibular Dysfunction and Cervical Posture in Different Occlusal Angle Classes in Adolescents
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Temporomandibular Dysfunction
Keywords: temporomandibular dysfunction
posture
Lead sponsor: University of Nove de Julho
Sponsor class: OTHER
First posted: 2011-04-08
Enrollment: 296
Sex: ALL
Minimum age (years): 10
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adolescents aged between 10 and 20 years. As criteria for inclusion, age group and the presence of first permanent molar

Brief summary: The aim of this research was to determine the existence of a correlation between the degree of temporomandibular dysfunction and cervical posture in different occlusal classes in adolescents. A cross-section, observational study was carried out, in which 296 adolescents took part. For the evaluation, the patients were divided into groups according to the presence and severity of the temporomandibular dysfunction, using a questionnaire and occlusal Angle classification. The posture analysis was carried out using photogrammetry and the software Alcimage® to measure the predefined angle based on the protuberances of the Spinous Process of the 7th Cervical Vertebra (C7), Manubrium of the sternum and Mentum Vertex.

Detailed description: The evaluation of signs and symptoms of TMD was obtained from a Questionnaire (15) which includes information regarding difficulties opening the mouth and movement of the mandible, pains in the head, nape of the neck, neck or joint regions, noise in the temporomandibular joints, and the habit of clenching or grinding the teeth. The questionnaire is comprised of 10 questions with possible answers of yes (10 points), sometimes (5 points) and no (0 points). For each question, only one answer can be checked. The total score is used to classify the severity of the TMD as severe (70 to 100 points), moderate (45 to 65), mild (20 to 40) and no dysfunction (0 to 15).

The clinical (visual) assessment of head posture was conducted using a postural grid. Each subject was asked to remain in his or her normal posture, in a standing position. The self balance position was used to standardize the posture of each subject, asking them to look straight ahead, parallel to the floor, keeping the gaze horizontal

Eligibility criteria: Inclusion Criteria:

* adolescents, aged between 10 and 20 years. As criteria for inclusion, age group and the presence of first permanent molar

Exclusion Criteria:

* Individuals undergoing orthodontic treatment, those with absent first molars and cases where it was impossible to clinically evaluate the occlusion were excluded.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Nove de Julho University
Study officials:
affiliation: Nove de Julho University
name: Lara Motta, Ms
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00002438: A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients
Official title: Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Histoplasmosis
Keywords: Itraconazole
Histoplasmosis
Acquired Immunodeficiency Syndrome
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: To assess the safety and efficacy of itraconazole versus placebo for prevention of histoplasmosis in HIV-infected patients with CD4 counts \< 150 cells/mm3 who reside where histoplasmosis is endemic. To assess the safety and efficacy of itraconazole for preventing other debilitating fungal infections, such as cryptococcosis, aspergillosis, recalcitrant oropharyngeal or vaginal candidiasis, and recurrent esophageal candidiasis.


Eligibility criteria: Inclusion Criteria

Patients must have:

* HIV infection.
* Residence in an area endemic for H. capsulatum.
* Absolute CD4 count \< 150 cells/mm3.
* No current or past active histoplasmosis.
* No other active fungal infection.
* Life expectancy of at least 1 year.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Life-threatening infection or malignancy other than cutaneous Kaposi's sarcoma.
* Inability to take oral medication.

Concurrent Medication:

Excluded:

* Systemically-active antifungals.
* Investigational drugs (expanded access drugs are acceptable).
* Rifampin.
* Rifabutin.
* Terfenadine.
* Astemizole.
* Phenobarbital.
* Phenytoin.
* Carbamazepine.
* H2 blockers.
* Omeprazole.
* Continual antacids.

Patients with the following prior conditions are excluded:

History of intolerance to imidazole or azole compounds.

Prior Medication:

Excluded within 1 month prior to study entry:

* Investigational drugs (expanded access drugs are acceptable).

Excluded within 15 days prior to study entry:

* Rifampin.
* Rifabutin.
* Terfenadine.
* Astemizole.
* Phenobarbital.
* Phenytoin.
* Carbamazepine.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Infectious Diseases Research Clinic / Indiana Univ Hosp
state: Indiana
city: Indianapolis
country: United States
facility: Infectious Diseases of Indianapolis
state: Indiana
city: Kansas City
country: United States
facility: Univ of Missouri at Kansas City School of Medicine
state: Missouri
city: Kansas City
country: United States
facility: Infectious Diseases Association / Research Med Ctr
state: Missouri
city: Memphis
country: United States
facility: ASCC
state: Tennessee
city: Memphis
country: United States
facility: Dr Michael Threikeld
state: Tennessee
city: Nashville
country: United States
facility: Dr Mark A Pierce
state: Tennessee
Study officials:
References:
Clinical trial NCT02580838: The Effects of Early and Late Injection of Botulinum Toxin Type A on Upper Limb Function in Patients With Stroke
Official title: The Effects of Early and Late Injection of Botulinum Toxin Type A on Upper Limb Function in Patients With Stroke
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Stroke
Keywords: Stroke
Spasticity
OnabotulinumtoxinA
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
First posted: 2015-10-20
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine whether early use of OnabotulinumtoxinA is more effective to improve functional outcomes of upper limb in patients with stroke.

Detailed description: Many patients surviving stroke have significant impairment of function in the affected upper limb due to the development of spasticity. Botulinum toxin type A injection is a powerful treatment option for control of spasticity. In this study, the patients will be randomly assigned into three groups: early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention. The aim of this randomized controlled study is to evaluate the effects of early and late injection of botulinum toxin type A on upper limb function in patients with stroke.

Eligibility criteria: Inclusion Criteria:

* stroke affecting one body side
* spasticity develops after stroke

Exclusion Criteria:

* musculoskeletal conditions that affected upper limb function prior to stroke
* concurrent use of anti-spasticity medications
* patients with neuromuscular junction or myopathic disorders such as myasthenia gravis or others
* patients with a known allergy to any onabotulinumtoxinA or to any of the excipients of onabotulinumtoxinA (such as human serum albumin)
* patients who are pregnant or may become pregnant at the time of the proposed injection

Primary outcomes:
measure: Modified Ashworth Scale
timeFrame: change from baseline Modified Ashworth Scale at 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital
Study officials:
affiliation: Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital
name: Richard Lin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02207738: Comparison of Efficacy Between Fractional Microneedling Radiofrequency and Bipolar Radiofrequency for Acne Scar
Official title: Comparative Study of Efficacy and Safety Between Fractional Microneedling Radiofrequency and Bipolar Radiofrequency Treatment for Acne Scar
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acne
Scar
Keywords: acne
acne scar
microneedling radiofrequency
bipolar radiofrequency
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2014-08-04
Enrollment: 23
Sex: ALL
Minimum age (years): 19
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Compare the efficacy and safety profile of microneedling radiofrequency and that of bipolar radiofrequency treatment for acne scar.

Detailed description: Efficacy and safety of microneedling radiofrequency for acne scar Efficacy and safety bipolar radiofrequency treatment for acne scar compare the efficacy and safety profile of microneedling radiofrequency and that of bipolar radiofrequency treatment for acne scar

Eligibility criteria: Inclusion Criteria:

* moderate acne scar
* mild to moderate acne lesions

Exclusion Criteria:

* taking acne medication oral drugs within 2 months topical drugs within 2 weeks
* taken anu procedures for acne scar within 6 months
* taking steroid,nonsteroidal antiinflammtory drugs, isotretinoin
* underlying diabetes mellitus, keloid, or any malignancy

Primary outcomes:
measure: Global assessment of acne scar
timeFrame: 12 weeks
Secondary outcomes:
measure: ECCA
timeFrame: 12 weeks
measure: Adverse effect
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Dermatology, Seoul National University College of Medicine
Study officials:
affiliation: Department of Dermatology, Seoul National University College of Medicine
name: Dae Hun Suh, PhD
role: STUDY_CHAIR
affiliation: Department of Dermatology, Seoul National University College of Medicine
name: Seonguk Min, Msc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yeung CK, Chan NP, Shek SY, Chan HH. Evaluation of combined fractional radiofrequency and fractional laser treatment for acne scars in Asians. Lasers Surg Med. 2012 Oct;44(8):622-30. doi: 10.1002/lsm.22063. Epub 2012 Aug 16.
Clinical trial NCT04217538: Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa
Official title: Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa That Come for Their Annual/Biannual Check up at This Medical Rare Disease Reference Centers (MRDRC) of This Disease in France and Belgium
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epidermolysis Bullosa
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2020-01-03
Enrollment: 41
Sex: ALL
Minimum age (years): 7
Maximum age (years): 78
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with EBH are recruted from the 2 MRDRC of the disease in France and the one of Belgium, the dental visit was/is organized for each visit/follow up of the patient in the center (annual or bianual visit)

Brief summary: Hereditary Epidermolysis Bullosa (EBH) are rare dermatologic diseases characterized by cutaneous and mucosa fragility. Oral manifestations of few small cohort have been published. The main objective of this multicentric cohort study first in Europe was to report the oral status of these patients that were consulted in the MRDRC of this disease in Nice (France), Toulouse (France) and Louvain (Belgium). Then a correlation between the oral characteristics and the EBH type will be made, in order to facilitate the management of patient care and the prevention program that can be established to improve their oral health.


Eligibility criteria: Inclusion Criteria:

* patient with EBH
* patient consent for examination and use the clinical data for publication purpose

Exclusion Criteria:

-

Primary outcomes:
measure: Dental structural abnormalities and/or caries
timeFrame: 1 day
Secondary outcomes:
measure: gingival biotype
timeFrame: 1 day
measure: gingival status
timeFrame: 1 day
measure: plaque and gingival index
timeFrame: 1 day
measure: oral lesion
timeFrame: 1 day
Other outcomes:
Locations:
city: Nice
country: France
facility: Nice Hospital
city: Toucy
country: France
facility: Toulouse University
Study officials:
References:
Clinical trial NCT06713408: Effects of Music and Affirmation Recital in Women With Breast Cancer
Official title: Music and Affirmation Recital on Symptom Control, Psychological Resilience and Anxiety Levels
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Keywords: Chemotherapy
Music
Lead sponsor: Amasya University
Sponsor class: OTHER
First posted: 2024-12-03
Enrollment: 71
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to determine the effect of music and affirmation recitals on symptom control, psychological resilience and anxiety levels in women with breast cancer.

Detailed description: Introduction: Music therapy is attracting attention today because it is a person-centered approach that does not require any special skills and/or significant financial investments.

Method: The aim of this study is to determine the effect of music and affirmation recitals on symptom control, psychological resilience and anxiety levels in women with breast cancer. This study will be conducted using a randomized controlled trial design. It is planned to include 75 women in total, 25 patients in the music recital group, 25 patients in the music and affirmation group and 25 patients in the control group. Data in the study will be collected using the Introductory Information Form, Edmonton Symptom Diagnostic Scale, State Anxiety Scale and Psychological Resilience Scale.

Conclusion: It is thought that the findings obtained in this study will contribute to the use of music and affirmation, which are cheap, effective and easily applicable methods, in chemotherapy units as a method to help reduce patients' anxiety. The study is expected to reduce the symptoms of breast cancer patients and reduce their anxiety levels

Eligibility criteria: Inclusion Criteria:

* Those diagnosed with breast cancer
* Those who have received at least 1 course of chemotherapy
* Those over the age of 18
* Those who agree to participate in the study

Exclusion Criteria:

* Those who are not receiving curative chemotherapy
* Those who do not have a phone to listen to music and affirmations
* Those who do not agree to participate in the study
* Those with mental and neuropsychiatric diseases

Primary outcomes:
measure: Edmonton Symptom Diagnostic Scale
timeFrame: 1 month
measure: Beck Anxiety Inventory
timeFrame: 1 month
measure: Brief Resilience Scale
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Amasya
country: Turkey
facility: Amasya University
Study officials:
References:
Clinical trial NCT01471808: Effects of Different Early Intensive Therapies on Long-term β-cell Function
Official title: Effects of Oral Hypoglycemic Agents Combined With Short-term CSII on Glycemic Control in Newly-diagnosed Type 2 Diabetic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
Collaborators: name: Nanfang Hospital, Southern Medical University
name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
name: Peking University Shenzhen Hospital
name: First People's Hospital of Foshan
First posted: 2011-11-16
Enrollment: 264
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate and evaluate the effects of different oral antihyperglycaemic agents combined with short-term continuous subcutaneous insulin infusion(CSII)(1.CSII alone; 2.metformin and pioglitazone combined with CSII; 3. sitagliptin combined with CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.


Eligibility criteria: Inclusion Criteria:

* newly diagnosed type 2 diabetes
* fasting blood glucose (FBG) level ranging from 7.0～16.7 mmol/L
* body mass index (BMI) ranging from21～35kg/m2
* Antihyperglycaemic and antihyperlipidemic medication-naive patients

Exclusion Criteria:

* having any severe acute or chronic diabetic complications
* renal dysfunction, blood creatinine≥150µmol/L
* blood aminotransferase level rising up(more than 2 times of the upper normal limit of ALT)
* • Any severe cardiac disease including congestive cardiac failure, unstable angina or myocardial infarct in 12 months
* chronic or acute pancreatic disease
* severe systematic diseases or malignant tumor
* female patients incline to be pregnant
* being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs
* poor compliance

Primary outcomes:
measure: glycemic control after short intensive therapy in newly diagnosed type 2 diabetic patients
timeFrame: 1 years
measure: the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients
timeFrame: 1 years
Secondary outcomes:
measure: the effects of different interventions on β-cell function in newly-diagnosed type 2 diabetic patients
timeFrame: 1 years
Other outcomes:
Locations:
Study officials:
affiliation: Ministry of Education
name: Yanbin Li, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Liu L, Ke W, Wan X, Zhang P, Cao X, Deng W, Li Y. Insulin requirement profiles of short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes and its association with long-term glycemic remission. Diabetes Res Clin Pract. 2015 May;108(2):250-7. doi: 10.1016/j.diabres.2015.02.011. Epub 2015 Feb 21.